Sign In  |  Register  |  About Pleasanton  |  Contact Us

Pleasanton, CA
September 01, 2020 1:32pm
7-Day Forecast | Traffic

  • Search Hotels in Pleasanton

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by Lantern Pharma Inc.

< Previous 1 2 Next >
Lantern Pharma & Starlight Therapeutics Present LP-184 (STAR-001) Phase 1b Trial Design and Preclinical Data in Glioblastoma at Society for Neuro-Oncology (SNO) 2024 Highlighting Novel Synthetic Lethality
From Lantern Pharma Inc.
Via Business Wire
Tickers LTRN
Lantern Pharma Announces First Patient Dosed in Japan for The Expansion Cohort in The Phase 2 HARMONIC™ Clinical Trial of LP-300 in Never-Smoker NSCLC Patients
From Lantern Pharma Inc.
Via Business Wire
Tickers LTRN
Lantern Pharma Reports Third Quarter 2024 Financial Results and Business Updates
From Lantern Pharma Inc.
Via Business Wire
Tickers LTRN
Starlight Therapeutics Announces Inaugural Members of Scientific Advisory Board
From Lantern Pharma Inc.
Via Business Wire
Tickers LTRN
Lantern Pharma to Report Third Quarter 2024 Operating & Financial Results on November 7th, 2024 at 4:30 p.m. ET
From Lantern Pharma Inc.
Via Business Wire
Tickers LTRN
Lantern Pharma to Present at the ThinkEquity Conference in NYC on October 30, 2024
From Lantern Pharma Inc.
Via Business Wire
Tickers LTRN
Lantern Pharma to Host & Participate in Two Public Webinars During October
From Lantern Pharma Inc.
Via Business Wire
Tickers LTRN
Lantern Pharma’s Investigational Drug-Candidate, LP-184, Receives Fast-Track Designation in Glioblastoma from the FDA
From Lantern Pharma Inc.
Via Business Wire
Tickers LTRN
Lantern Pharma Announces Three U.S. FDA Rare Pediatric Disease Designations Granted to LP-184 in Multiple Ultra Rare Children’s Cancers
From Lantern Pharma Inc.
Via Business Wire
Tickers LTRN
Lantern Pharma Reports Second Quarter 2024 Financial Results and Business Updates
From Lantern Pharma Inc.
Via Business Wire
Tickers LTRN
Lantern Pharma to Report Second Quarter 2024 Operating & Financial Results on August 8th, 2024 at 4:30 p.m. ET
From Lantern Pharma Inc.
Via Business Wire
Tickers LTRN
Lantern Pharma Receives Certificate of Patent from Japanese Patent Office (JPO) for Composition of Matter Covering Drug Candidate LP-284
From Lantern Pharma Inc.
Via Business Wire
Tickers LTRN
Lantern Pharma Reports First Quarter 2024 Financial Results and Business Highlights
From Lantern Pharma Inc.
Via Business Wire
Tickers LTRN
Oregon Therapeutics & Lantern Pharma Launch Strategic AI Collaboration to Optimize Development of First-In-Class Drug Candidate XCE853 – A Potent Inhibitor of Cancer Metabolism
From Lantern Pharma Inc.
Via Business Wire
Tickers LTRN
Lantern Pharma to Report First Quarter 2024 Operating & Financial Results on May 9th, 2024 at 4:30 p.m. ET
From Lantern Pharma Inc.
Via Business Wire
Tickers LTRN
Lantern Pharma Launches “Webinar Wednesdays” Featuring World-Class Physician Scientists & Key Opinion Leaders Discussing Critical Areas of Oncology Drug Development
From Lantern Pharma Inc.
Via Business Wire
Tickers LTRN
Lantern Pharma Receives Regulatory Approval to Expand Harmonic™ Clinical Trial for Non-Small Cell Lung Cancer in Never-Smokers into Japan and Taiwan
From Lantern Pharma Inc.
Via Business Wire
Tickers LTRN
Lantern Pharma Reports Fourth Quarter & Fiscal Year 2023 Financial Results and Business Highlights
From Lantern Pharma Inc.
Via Business Wire
Tickers LTRN
Lantern Pharma Announces Initial Patients Dosed in First-In-Human Clinical Trial for AI-Guided Drug-Candidate, LP-284
From Lantern Pharma Inc.
Via Business Wire
Tickers LTRN
Lantern Pharma to Report Fourth Quarter and Fiscal Year 2023 Operating & Financial Results on March 18th, 2024 at 4:30 p.m. ET
From Lantern Pharma Inc.
Via Business Wire
Tickers LTRN
Lantern To Participate in H.C Wainwright & Co.’s (HCW) 1st Annual Artificial Intelligence Based Drug Discovery & Development Virtual Conference
From Lantern Pharma Inc.
Via Business Wire
Tickers LTRN
Lantern Pharma's A.I. Platform, RADR®, Surpasses 60 Billion Data Points – Anticipates Reaching 100 Billion Data Points in 2024, Paving the Way for Enhanced Cancer Therapy Innovations and Expedited Development Timelines
From Lantern Pharma Inc.
Via Business Wire
Tickers LTRN
Lantern Pharma Advances Unique ADC (Antibody Drug Conjugate) Program Across Multiple Solid Tumor Cancers
From Lantern Pharma Inc.
Via Business Wire
Tickers LTRN
FDA Grants Lantern Pharma Orphan Drug Designation for Drug Candidate LP-284 in High-Grade B-cell Lymphomas (HGBL)
From Lantern Pharma Inc.
Via Business Wire
Tickers LTRN
Lantern Pharma Reports Third Quarter 2023 Financial Results and Operational Highlights
From Lantern Pharma Inc.
Via Business Wire
Tickers LTRN
Lantern Pharma to Report Third Quarter 2023 Operating & Financial Results on November 8th, 2023 at 4:30 p.m. ET
From Lantern Pharma Inc.
Via Business Wire
Tickers LTRN
Lantern Pharma to Present at the ThinkEquity Conference on October 19 at 1:30 p.m. ET
From Lantern Pharma Inc.
Via Business Wire
Tickers LTRN
Lantern Pharma Announces First Patient Dosed in the Phase 1 Study for LP-184 in Advanced Solid Tumors
From Lantern Pharma Inc.
Via Business Wire
Tickers LTRN
Lantern Pharma Receives IND Clearance from FDA Enabling Phase 1 Initiation for Drug Candidate LP-284 in Non-Hodgkin’s Lymphomas
From Lantern Pharma Inc.
Via Business Wire
Tickers LTRN
Lantern Pharma to Present Data Highlighting the Anti-Tumor Potency of Drug Candidate LP-284 in Non-Hodgkin’s Lymphomas at the Society of Hematologic Oncology Annual Meeting
From Lantern Pharma Inc.
Via Business Wire
Tickers LTRN
< Previous 1 2 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Photography by Christophe Tomatis
Copyright © 2010-2020 Pleasanton.com & California Media Partners, LLC. All rights reserved.